Patents by Inventor Roger A. Bakale

Roger A. Bakale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220194971
    Abstract: Compounds are provided having the structure of Formula (I) or (II) or a pharmaceutically acceptable salt, homolog, hydrate or solvate thereof, wherein Ra, Rd and Re are as defined herein. Such compounds serve as modulators of the sphingosine-1-phosphate receptor, and have utility for treatment of a malcondition for which activation of this receptor is medically indicated.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 23, 2022
    Inventors: Philip Turnbull, Roger Bakale, Jeff Schkeryantz, Maurice Marsini
  • Publication number: 20220194908
    Abstract: Compounds are provided having the structure of Formula (I), or a pharmaceutically acceptable salt, homolog, hydrate or solvate thereof, wherein Rb1 and Rb2 are as defined herein. Such compounds serve as modulators of the sphingosine-1-phosphate receptor, and have utility for treatment of a malcondition for which activation of this receptor is medically indicated.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 23, 2022
    Inventors: Philip Turnbull, Roger Bakale, Maurice Marsini
  • Publication number: 20220144788
    Abstract: Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable salt, homolog, hydrate or solvate thereof, wherein Ra is as defined herein. Such compounds serve as modulators of the sphingosine-1-phosphate receptor, and have utility for treatment of a malcondition for which activation of this receptor is medically indicated.
    Type: Application
    Filed: March 27, 2020
    Publication date: May 12, 2022
    Inventors: Philip Turnbull, Roger Bakale, Jeff Schkeryantz, Maurice Marsini
  • Patent number: 11066395
    Abstract: Crystalline 2-hydroxy-N,N-dimethylethanaminium 1-(2-(5-(tert-butyl)-thiophene-2-carboxamido)-3-(4-(5-(4?-ethyl-[1,1?-bi(cyclohexan)]-3-en-4-yl)pyrimidin-2-yl)phenyl)propanoyl)azetidine-3-carboxylate salt, and methods related to synthesis and therapeutic use of the same.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: July 20, 2021
    Assignee: RECEPTOS LLC
    Inventors: Ephraim Vidal, Roger Bakale, Philip Turnbull, David Moser, Andrew Robbins, Craig Grant
  • Publication number: 20200131164
    Abstract: Crystalline 2-hydroxy-N,N-dimethylethanaminium 1-(2-(5-(tert-butyl)-thiophene-2-carboxamido)-3-(4-(5-(4?-ethyl-[1,1?-bi(cyclohexan)]-3-en-4-yl)pyrimidin-2-yl)phenyl)propanoyl)azetidine-3-carboxylate salt, and methods related to synthesis and therapeutic use of the same.
    Type: Application
    Filed: September 29, 2017
    Publication date: April 30, 2020
    Inventors: Ephraim Vidal, Roger Bakale, Philip Turnbull, David Moser, Andrew Robbins, Craig Grant
  • Publication number: 20180222845
    Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
    Type: Application
    Filed: October 18, 2017
    Publication date: August 9, 2018
    Inventors: Paul McGlynn, Roger BAKALE, Craig STURGE
  • Publication number: 20160368858
    Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
    Type: Application
    Filed: January 22, 2016
    Publication date: December 22, 2016
    Inventors: Paul McGlynn, Roger Bakale, Craig Sturge
  • Publication number: 20150071969
    Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
    Type: Application
    Filed: May 21, 2014
    Publication date: March 12, 2015
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Paul MCGLYNN, Roger Bakale, Craig Sturge
  • Patent number: 8765153
    Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: July 1, 2014
    Inventors: Paul McGlynn, Roger Bakale, Craig Sturge
  • Publication number: 20130236515
    Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
    Type: Application
    Filed: April 29, 2013
    Publication date: September 12, 2013
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Paul MCGLYNN, Roger BAKALE, Craig STURGE
  • Publication number: 20130028845
    Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
    Type: Application
    Filed: October 2, 2012
    Publication date: January 31, 2013
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Paul McGlynn, Roger Bakale, Craig Sturge
  • Publication number: 20100272654
    Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
    Type: Application
    Filed: July 9, 2010
    Publication date: October 28, 2010
    Inventors: Paul McGlynn, Roger Bakale, Craig Sturge
  • Publication number: 20080119564
    Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
    Type: Application
    Filed: August 8, 2007
    Publication date: May 22, 2008
    Inventors: Paul McGlynn, Roger Bakale, Craig Sturge
  • Patent number: 7256310
    Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
    Type: Grant
    Filed: December 8, 2003
    Date of Patent: August 14, 2007
    Assignee: Sepracor Inc.
    Inventors: Paul McGlynn, Roger Bakale, Craig Sturge
  • Publication number: 20060035940
    Abstract: One aspect of the present invention relates to optically pure (S)-amlodipine malate. Another aspect of the present invention relates to (rac)-amlodipine malate. In a preferred embodiment, the compound is optically pure (S)-amlodipine L-malate. Another aspect of the present invention relates to a pharmaceutical composition comprising optically pure (S)-amlodipine malate. Another aspect of the present invention relates to a method of preparing optically pure (S)-amlodipine malate, comprising admixing optically pure (S)-amlodipine with malic acid. Another aspect of the present invention relates to the various polymorphic and solvated forms of optically pure (S)-amlodipine malate. In another prefered embodiment the invention relates to polymorphic and solvated forms A-G. The present invention also relates to a method of preparing optically pure (S)-amlodipine malate, comprising combining a salt of optically pure (S)-amlodipine with a malate salt to give optically pure (S)-amlodipine malate.
    Type: Application
    Filed: March 16, 2005
    Publication date: February 16, 2006
    Applicant: Sepracor Inc.
    Inventors: Sharon Laughlin, Roger Bakale, Harold Wilkinson, Andrei Zlota
  • Publication number: 20060030602
    Abstract: One aspect of the present invention relates to optically pure (S)-amlodipine malate. Another aspect of the present invention relates to (rac)-amlodipine malate. In a preferred embodiment, the compound is optically pure (S)-amlodipine L-malate. Another aspect of the present invention relates to a pharmaceutical composition comprising optically pure (S)-amlodipine malate. Another aspect of the present invention relates to a method of preparing optically pure (S)-amlodipine malate, comprising admixing optically pure (S)-amlodipine with malic acid. Another aspect of the present invention relates to the various polymorphic and solvated forms of optically pure (S)-amlodipine malate. In another prefered embodiment the invention relates to polymorphic and solvated forms A-G. The present invention also relates to a method of preparing optically pure (S)-amlodipine malate, comprising combining a salt of optically pure (S)-amlodipine with a malate salt to give optically pure (S)-amlodipine malate.
    Type: Application
    Filed: March 16, 2005
    Publication date: February 9, 2006
    Applicant: Sepracor Inc.
    Inventors: Sharon Laughlin, Roger Bakale, Harold Wilkinson, Andrei Zlota
  • Publication number: 20060025418
    Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (?)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (?)-N-desmethylzopiclone.
    Type: Application
    Filed: September 20, 2005
    Publication date: February 2, 2006
    Inventors: Thomas Jerussi, Chrisantha Senanayake, Paul Rubin, Yaping Hong, Roger Bakale, Tingjian Xiang, Fran McConville
  • Patent number: 6946464
    Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (?)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (?)-N-desmethylzopiclone.
    Type: Grant
    Filed: January 13, 2003
    Date of Patent: September 20, 2005
    Assignee: Sepracor Inc.
    Inventors: Thomas P. Jerussi, Chrisantha H. Senanayake, Paul D. Rubin, Yaping Hong, Roger A. Bakale, Tingjian Xiang, Fran A. McConville
  • Publication number: 20050009887
    Abstract: The invention relates to methods of resolving racemic amlodipine into enantiomerically enriched compositions by precipitation with tartaric acid in the presence of a non-aqueous solvent, such as N,N?-dimethylacetamide. The molar ratio of tartaric acid:amlodipine is preferably less than 0.25:1.0 or greater than 0.75:1.0.
    Type: Application
    Filed: August 4, 2004
    Publication date: January 13, 2005
    Applicant: Sepracor Inc.
    Inventors: Chris Senanayake, Gerald Tanoury, Harold Wilkinson, Roger Bakale, Andrei Zlota, Kostas Saranteas
  • Publication number: 20040115136
    Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.
    Type: Application
    Filed: December 8, 2003
    Publication date: June 17, 2004
    Inventors: Paul McGlynn, Roger Bakale, Craig Sturge